<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02778360</url>
  </required_header>
  <id_info>
    <org_study_id>Newrofeed</org_study_id>
    <nct_id>NCT02778360</nct_id>
  </id_info>
  <brief_title>Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder</brief_title>
  <acronym>Newrofeed</acronym>
  <official_title>Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) as Compared With Methylphenidate in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Multicentre Randomized Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mensia Technologies SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union H2020 SME Instrument</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mensia Technologies SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to demonstrate the non-inferiority of the personalized
      Neurofeedback Training device versus Methylphenidate in the treatment of children and
      adolescents with Attention-Deficit/Hyperactivity Disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the present study is to demonstrate the non-inferiority of the
      personalized Neurofeedback Training device ADHD@Home versus Methylphenidate in the treatment
      of children and adolescents with Attention-Deficit/Hyperactivity Disorder.

      Furthermore, it is aimed to learn more about the mechanisms underlying NeuroFeedback.

      The study is prospective, multicentric (9 centres), randomised, reference drug-controlled.

      ADHD@Home is a neuromarkerTM-based personalized medicine device to treat children suffering
      from Attention Deficit Hyperactivity Disorders (ADHD) with Neurofeedback Training (NFT) based
      on real time electroencephalography (EEG) signal.

      Neurofeedback Training is based on direct training of brain function, by which the brain
      learns to function more efficiently. For each session of the ADHD@Home solution, the child is
      trained to modulate his brain activity in a serious game, which is a real-time metaphor of
      the EEG biomarker that needs to be 'normalized', following a typical operant learning
      process.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Day 0 at Day 90 of the total score of the ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV)</measure>
    <time_frame>3 times (Day 0, Day 60, Day 90)</time_frame>
    <description>ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): total score assessed by the clinician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD RS IV Inattention and Hyperactivity Sub-Scores</measure>
    <time_frame>3 times (Day 0, Day 60, Day 90)</time_frame>
    <description>ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Inattention and Hyperactivity sub-scores assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical responders</measure>
    <time_frame>1 time (Day 90)</time_frame>
    <description>Clinical responders are subjects who will present a decrease of the total clinician ADHD RS score of more or equal to 25%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents ADHD RS IV Total, Inattention and Hyperactivity Scores</measure>
    <time_frame>3 times (Day 0, Day 60, Day 90)</time_frame>
    <description>ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Total, Inattention and Hyperactivity scores assessed by the parents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Teacher ADHD RS IV Total, Inattention and Hyperactivity Scores</measure>
    <time_frame>2 times (Day 0, Day 90)</time_frame>
    <description>ADHD RS IV (Attention Deficit Hyperactivity Disorder Rating Scale IV): Total, Inattention and Hyperactivity scores assessed by the teacher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (severity) (CGI-S)</measure>
    <time_frame>7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>Severity of the illness assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (improvement) (CGI-I)</measure>
    <time_frame>6 times (Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>Improvement of the patient's condition assessed by the clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Behavior Rating Inventory of Executive Function (BRIEF)</measure>
    <time_frame>2 times (Day 0, Day 90)</time_frame>
    <description>Executive Function Tests by the Behavior Rating Inventory of Executive Function (BRIEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conners Continuous Performance Test 3rd Edition (Conners CPT 3)</measure>
    <time_frame>2 times (Day 0, Day 90)</time_frame>
    <description>Conners Continuous Performance Test 3rd Edition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strengths and Difficulties Questionnaire (SDQ)</measure>
    <time_frame>2 times (Day 0, Day 90)</time_frame>
    <description>Behaviour assessment by the parents and the teacher with the Strengths and Difficulties Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quantitative Electro-Encephalogram (qEEG)</measure>
    <time_frame>3 times (Day 0, Day 60, Day 90)</time_frame>
    <description>Quantitative electroencephalogram to assess EEG biomarkers, progress in brain modulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia suicide severity rating scale (C-SSRS)</measure>
    <time_frame>7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>Columbia suicide severity rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Disturbance Scale for Children (SDSC)</measure>
    <time_frame>7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>Sleep Disturbance Scale for Children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric adverse event rating scale (PAERS)</measure>
    <time_frame>7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>Pediatric adverse event rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>1 time (Day 0)</time_frame>
    <description>Physical examination will include assessments of height, weight, cardiac frequency, cardiac exam and blood pressure.
Investigator will question the parents about the cardiac history of the family and on individual risk factors. If a risk factor is detected, the patient will be addressed to a cardiologist for an electrocardiogram (ECG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical/surgical history</measure>
    <time_frame>1 time (Day 0)</time_frame>
    <description>Assessment especially related to the eligibility criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant treatments collection</measure>
    <time_frame>7 times (Day 0, Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>All the treatments taken during the participation will be collected (trade name, indication, dose, onset/end dates).
The use of concomitant medications will be summarized by therapeutic class.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events collection</measure>
    <time_frame>6 times (Day 7, Day 14, Day 21, Day 28, Day 60, Day 90)</time_frame>
    <description>All the adverse events occurred during the participation will be collected until resolution or stabilization (description/symptoms, onset/end dates, frequency, intensity, evolution, causality to treatment attributed, seriousness).
All adverse events will be described in each arm. A comparison will be done, especially concerning number and percentage of patients who experienced at least one adverse event (on the whole and by system/organ), at least one adverse event leading to discontinue the treatment, and at least one serious adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Health and Illness Profile, Child Edition (CHIP-CE)</measure>
    <time_frame>2 times (Day 0, Day 90)</time_frame>
    <description>Measure of the quality of life by the parents with the CHIP-CE parents report form</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">179</enrollment>
  <condition>Attention Deficit-Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Neurofeedback NFT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neurofeedback Training based on real time electroencephalography (EEG) signal. The patient is trained to modulate his brain activity thanks to a tablet installed with serious game.
Initiation/Discovery period during 21 days: initiation and discovery sessions Treatment period during 9 weeks: 36 training sessions at home</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylphenidate MPH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methylphenidate long acting preparation.
Open titration protocol during 21 days: 10 mg/day as a start until optimal dose is reached (maximum dose: 60 mg/day).
Treatment period during 9 weeks: optimal dose with MPH LA 10 and 30 mg (dose range: 10 mg/day to 60 mg/day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurofeedback NFT</intervention_name>
    <description>The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.
The training is personalized according to patient's characteristics.</description>
    <arm_group_label>Neurofeedback NFT</arm_group_label>
    <other_name>Neurofeedback training</other_name>
    <other_name>ADHD@Home</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylphenidate MPH</intervention_name>
    <description>Drug prescribed with a first titration period until an optimal dose.</description>
    <arm_group_label>Methylphenidate MPH</arm_group_label>
    <other_name>Methylphenidate long acting</other_name>
    <other_name>Medikinet retard</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children or adolescents (male or female) aged 7-13 years

          -  ADHD diagnosis positive with Kiddie-Sads

          -  ADHD RS IV &gt;6 for attention, with or without hyperactivity

          -  Patient having already had corrective actions for ADHD (formal and informal
             educational support, psychoeducation, psychotherapy, occupational therapy remediation,
             at-school programs and remediations)

          -  Signature of inform consent form by parent and child

          -  Wireless internet connection at home

        Exclusion Criteria:

          -  ADHD hyperactive/Impulsive without inattention component

          -  Established diagnosis of epilepsy or other neurological disorders

          -  Severe and/or uncontrolled psychiatric disorder other than ADHD diagnosed with
             Kiddie-Sads such as autism, schizophrenia, severe generalized anxiety disorder, major
             depression or severe tics

          -  Patient with comorbid disorder requiring psychoactive medication other than ADHD
             medication

          -  Patient having already been treated with psycho-active drug (MPH and others) or EEG-NF
             for ADHD in the last 6 months, or more than 4 weeks more than 6 months ago

          -  Unable to use the solution (tablet use and/or headset set-up and/or understanding
             instructions) according to the investigator

          -  Absence of wireless internet connection at home

          -  Medical disorder requiring systemic chronic medication with confounding psychoactive
             effects

          -  IQ &lt; 80 using the 3 subtest form of the WASI or the WISC

          -  Plans to move requiring centre change during the next 6 months

          -  Plans to start other ADHD treatment, including psychotherapy, cognitive behaviour
             training in the next 6 months

          -  Patient with chronic medical illness such as seizure, cardiac disorders, untreated
             thyroid disease or glaucoma (contra-indication for treatment with MPH)

          -  Significant suicidal risk based on clinical opinion

          -  Patient with prescribed dietary interventions

          -  Patient with a known hypersensitivity to one of the ingredients of the investigational
             products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel Du Peloux, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Mensia Technologies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane Purper-Ouakil, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Du Peloux, PhD</last_name>
    <phone>062-434-1061</phone>
    <phone_ext>+33</phone_ext>
    <email>michel.du-peloux@mensiatech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PSY Pluriel Centre europeen de psychologie medicale</name>
      <address>
        <city>Bruxelles</city>
        <zip>1080</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Victoor, MD/PhD</last_name>
      <phone>(0)2331-5665</phone>
      <phone_ext>+32</phone_ext>
      <email>lvictoor@psypluriel.be</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Souery, MD/PhD</last_name>
      <phone>(0)2331-5665</phone>
      <phone_ext>+32</phone_ext>
      <email>dsouery@psypluriel.be</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Victoor, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme - Cliniques universitaires de Bruxelles</name>
      <address>
        <city>Bruxelles</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie Delhaye, MD, PhD</last_name>
      <phone>(0)2 555 37 30</phone>
      <phone_ext>+32</phone_ext>
      <email>Marie.Delhaye@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Kristell Ackerman, MD, PhD</last_name>
      <phone>(0)2 555 35 96</phone>
      <phone_ext>+32</phone_ext>
      <email>kristell.ackerman@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Marie Delhaye, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Bioulac, MD/PhD</last_name>
      <email>stephanie.bioulac@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Stephanie Bioulac, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Fontan - Service de psychiatrie de l'enfant et de l'adolescent</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud Jardri, Pr</last_name>
      <email>Renaud.JARDRI@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aesa Parenti, MD, PhD</last_name>
      <phone>(0)3 20 44 67 47</phone>
      <phone_ext>+33</phone_ext>
      <email>AESA.PARENTI@chru-lille.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Renaud Jardri, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique LAUTREAMONT</name>
      <address>
        <city>Lille</city>
        <zip>59120</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Kochman, MD/PhD</last_name>
      <phone>(0)82-610-9990</phone>
      <phone_ext>+33</phone_ext>
      <email>f.kochman@orpea.net</email>
    </contact>
    <investigator>
      <last_name>Frederic Kochman, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospice Civil de Lyon - Hôpital Neurologique Service de Neuro-Psychiatrie de l'Enfant</name>
      <address>
        <city>Lyon</city>
        <zip>59003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Revol, MD, PhD</last_name>
      <email>olivier.revol@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Revol, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Purper-Ouakil, MD/PhD</last_name>
      <phone>(0)4 67 33 60 09</phone>
      <phone_ext>+33</phone_ext>
      <email>d-purper_ouakil@chu.montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Diane Purper-Ouakil, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Medical faculty of Mannheim/Heidelberg university</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Brandeis, DSc/Pr</last_name>
      <phone>(0)621 1703 4922</phone>
      <phone_ext>+49</phone_ext>
      <email>daniel.brandeis@zi-mannheim.de</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Banaschewski, MD/PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Tobias Banaschewski, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerta de Hierro Hospital - Department of Psychiatry</name>
      <address>
        <city>Madrid</city>
        <zip>28400</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilario Blasco-Fontecilla, MD/PhD</last_name>
      <phone>(0)91 8503008</phone>
      <phone_ext>+34</phone_ext>
      <email>hmblasco@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Hilario Blasco-Fontecilla, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Grangettes</name>
      <address>
        <city>Genève</city>
        <zip>1206</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline C Menache, MD/PhD</last_name>
      <phone>(0)22 305 0567</phone>
      <phone_ext>+41</phone_ext>
      <email>caroline.menache@grangettes.ch</email>
    </contact>
    <investigator>
      <last_name>Caroline Menache, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Psychiatric Hospital, University of Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>CH- 8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Brandeis, MSc/Pr</last_name>
      <phone>(0)43 499 2763</phone>
      <phone_ext>+41</phone_ext>
      <email>brandeis@kjpd.uzh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Susanne Walitza, MD/MSc/Pr</last_name>
      <phone>(0)43 499 27 30</phone>
      <phone_ext>+41</phone_ext>
      <email>susanne.walitza@puk.zh.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Susanne Walitza, MD/MSc/Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Attention deficit</keyword>
  <keyword>Neurofeedback</keyword>
  <keyword>ADHD</keyword>
  <keyword>Methylphenidate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

